Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 2 May 2014.
Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl. 7):vii252–61.
Kearney PL, Watkins JM, Shirai K, Wahlquist AE, Fortney JA, Garrett-Mayer E, et al. Salvage resection for isolated local and/or regional failure of head/neck cancer following definitive concurrent chemoradiotherapy case series and review of the literature. McGill J Med. 2011;13(2):29.
Lee DH, Roh J-L, Baek S, Jung JH, Choi S-H, Nam SY, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149(4):579–86.
Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt. 2 Suppl. 93):1–18.
De Visscher AV, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg. 1994;120(9):934–9.
Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–9.
Maguire PD, Meyerson MB, Neal CR, Hamann MS, Bost AL, Anagnost JW, et al. Toxic cure: hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys. 2004;58(3):698–704.
Meyer F, Fortin A, Wang CS, Liu G, Bairati I. Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol. 2012;82(4):1454–62.
Oral Care Study Group. Evidence-based management strategies for oral complication from cancer treatment. MASCC/ISOO; 2011. http://www.mascc.org/isoo. Accessed 10 Feb 2014.
Montero-Miranda PH, Ganly I. Survivorship—competing mortalities, morbidities, and second malignancies. Otolaryngol Clin North Am. 2013;46(4):681–710.
Simo R, Homer J. Follow-up of head and neck cancers. In: Roland NJ, Paleri V, editors. Head and neck cancer: multidisciplinary management guidelines. London: ENT-UK; 2011. p. 362–6.
Manikantan K, Khode S, Dwivedi RC, Palav R, Nutting CM, Rhys-Evans P, et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev. 2009;35(8):744–53.
Schwartz DL, Barker J Jr., Chansky K, Yueh B, Raminfar L, Drago P, et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma—too much for too little? Head Neck. 2003;25(12):990–9.
Joshi A, Calman F, O’Connell M, Jeannon J-P, Pracy P, Simo R. Current trends in the follow-up of head and neck cancer patients in the UK. Clin Oncol. 2010;22(2):114–8.
National Comprehensive Cancer Network. Head and Neck Cancers (v. 2.2013). http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 5 Feb 2014.
Gregoire V, Lefebvre J-L, Licitra L, Felip E, On behalf of the EHNS-ESMO-ESTRO guidelines working group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v184–6.
Merkx MAW, van Gulick JJM, Marres HAM, Kaanders JHAM, Bruaset I, Verbeek A, et al. Effectiveness of routine follow-up of patients treated for T1-2N0 oral squamous cell carcinomas of the floor of mouth and tongue. Head Neck. 2006;28(1):1–7.
Bar-Ad V, Mishra M, Ohri N, Intenzo C. Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma. Rev Recent Clin Trials. 2012;7(1):36–41.
Talwar B, Donnelly R. Nutrition. In: Roland NJ, Paleri V, editors. Head and neck cancer: multidisciplinary management guidelines. London: ENT-UK; 2011. p. 72–83.
Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26(22):3770–6.
Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, et al. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol. 2013;8(1):259.
Mitchell DH, Swift G, Gilbert GL. Surgical wound infection surveillance: the importance of infections that develop after hospital discharge. Aust N Z J Surg. 1999;69(2):117–20.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.
Denaro N, Merlano MC, Russi EG. Dysphagia in head and neck cancer patients: pretreatment evaluation, predictive factors, and assessment during radio-chemotherapy, recommendations. Clin Exp Otorhinolaryngol. 2013;6(3):117.
Langendijk JA, Doornaert P, Rietveld DHF, Verdonck-de Leeuw IM, René Leemans C, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol. 2009;90(2):189–95.
Kraaijenga SAC, van der Molen L, van den Brekel MWM, Hilgers FJM. Current assessment and treatment strategies of dysphagia in head and neck cancer patients: a systematic review of the 2012/13 literature. Curr Opin Support Palliat Care. 2014;8(2):152–63.
Do K-A, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003;14(2):131–8.
Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):242–74.